OTHER FUNCTIONS - IMPLANTABLE BATTERYLESS PACEMAKER AND TELEMETRY DEVICE FOR SMA

其他功能 - 植入式无电池起搏器和 SMA 遥测装置

• 批准号: 8564134
• 负责人: SRIDHAR MADALA
• 金额: $ 132.98万
• 依托单位: INDUS INSTRUMENTS
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-12-12 至 2013-12-11
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8564134
• 关键词: Accounting; Action Potentials; Adult; American; Animals; Arrhythmia; Atrial Fibrillation; Biocompatible; Cardiac; Cephalic; Cessation of life; Characteristics; Chronic; Clinical; Communication; Computer software; Contracts; Development; Devices; Electrocardiogram; Electrodes; Electronics; Electrophysiology (science); Fibrosis; Genetic; Goals; Heart; Heart Atrium; Heart Rate; Heart failure; Histologic; Implant; Knockout Mice; Lead; Left; Life; Link; Location; Longitudinal Studies; Measurement; Metals; Microelectrodes; Modeling; Monitor; Mus; Muscle Cells; Pacemakers; Personal Computers; Phase; Physiologic pulse; Polychlorinated Biphenyls; Protocols documentation; Public Health; Right atrial structure; Risk; Shapes; Silicones; Stainless Steel; Sterility; Telemetry; Testing; Tissues; Transgenic Mice; Ventricular Fibrillation; Wireless Technology; base; data acquisition; design; flexibility; heart electrical activity; heart rhythm; implantable device; implantation; in vivo; light weight; meetings; miniaturize; operation; parylene; programs; sudden cardiac death

Cardiac arrhythmias are a major public health burden. There are 250,000 - 400,000 sudden cardiac deaths (SCD) in the US every year, accounting for up to 20% of all deaths in adults; the majority of these are due to ventricular fibrillation. In addition, approximately 2.5 million Americans now suffer atrial fibrillation (AF), a number that is expected to surpass 5 million by 2050. Strong evidence indicates that risk for both SCD and AF include a prominent genetic component. Genetically-modified mice are a powerful model to study mechanisms underlying cardiac arrhythmias and heart failure. In larger animals, clinical pacemakers can be used to develop models of chronic AF or pacing-induced heart failure, among others. However, it has not been possible to develop similar models in transgenic or knockout mice due to the lack of availability of miniature, implantable pacemakers. Existing implantable telemetry devices for cardiac monitoring in small animals are either too large, too heavy, or have inadequate battery life. Moreover, these devices are not able to pace the hearts, which is essential for the development of the above models. The goal of this contract is to develop a small (<1cc), light-weight (<1gram), batteryless, wireless programmable implantable device for in vivo stimulation and monitoring of cardiac electrical activity in mice and other small animals. With batteryless operation by resonant inductive power transfer and wireless operation with a standard mouse cage, such a device will be suitable for long-term, ambulatory pacing and ECG monitoring in mice.

心律失常是一个主要的公共卫生负担。美国每年有25万至40万例心脏性猝死（SCD），占成人死亡总数的20%；其中大多数是由于心室颤动。此外，目前大约有250万美国人患有心房颤动（AF），预计到2050年这一数字将超过500万。强有力的证据表明，SCD和房颤的风险包括一个突出的遗传因素。转基因小鼠是研究心律失常和心力衰竭机制的有力模型。在大型动物中，临床起搏器可用于开发慢性房颤或起搏器诱发的心力衰竭等模型。然而，由于缺乏可植入的微型起搏器，在转基因或基因敲除小鼠中开发类似的模型是不可能的。现有的用于小动物心脏监测的植入式遥测设备要么太大，要么太重，要么电池寿命不足。此外，这些设备无法对心脏进行起搏，而这对上述模型的发展至关重要。该合同的目标是开发一种小（<1cc）、轻（<1g）、无电池、无线可编程的植入式设备，用于小鼠和其他小动物的体内刺激和心脏电活动监测。该装置采用谐振感应功率传输无电池操作，并与标准鼠笼无线操作，适用于小鼠长期动态起搏和心电监测。